Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $25,000.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $12.50, for a total transaction of $25,000.00. Following the completion of the transaction, the president now directly owns 2,924,467 shares of the company’s stock, valued at approximately $36,555,837.50. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Price Performance

Shares of GYRE opened at $10.79 on Friday. The firm has a 50-day moving average of $12.49 and a 200-day moving average of $12.67. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $27.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GYRE. FMR LLC bought a new position in shares of Gyre Therapeutics in the 3rd quarter valued at about $47,000. Barclays PLC lifted its stake in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after buying an additional 6,855 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth about $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth about $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth about $218,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.